AbCellera Biologics Inc. (ABCL) stock forecast and price target
Price $11.49 · data as of November 13, 2026
12-month price target
Average target$18.00
Upside / downside+56.7%
Analysts12
ConsensusStrong buy
Low $12.00Average $18.00High $30.00
Gold marker: average target · white marker: today’s price ($11.49)
Analyst ratings
Strong buy 2Buy 10Hold 1Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.60 | −23.2% | $31M |
| Next fiscal year ends December 31, 2027 | $-0.70 | −16.0% | $35M |
| Next quarter ends December 31, 2026 | $-0.16 | −442.4% | $8M |
| Quarter after ends December 31, 2026 | $-0.17 | −460.0% | $10M |
Consensus of the analysts covering AbCellera Biologics, updated daily. In the last 30 days 1 estimates were raised and 3 lowered.
Frequently asked questions
What is the AbCellera Biologics stock price target?
The average 12-month target from 12 analysts is $18.00, 56.7% above the current price of $11.49 Targets range from $12.00 to $30.00.
Is AbCellera Biologics a buy according to analysts?
The consensus rating is “Strong buy” (2 strong buy, 10 buy, 1 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is AbCellera Biologics expected to earn?
Analysts expect EPS of $-0.60 for the fiscal year ending December 31, 2026 and $-0.70 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.